作者: Inês F Pinto , Maria Raquel Aires-Barros , Ana M Azevedo
DOI: 10.4155/PBP.15.7
关键词:
摘要: The commercial potential of monoclonal antibodies (mAbs) has been continuously increasing during the last years alongside with number approved mAb-based drugs and clinical trials. Despite their effectiveness safety, general access to this class biopharmaceuticals is barred by high selling prices. Downstream processing now considered bottleneck in manufacturing mAbs. Therefore, design novel economic operations implementation current technology platforms constitutes a pressing need. This review provides an insight into state-of-the-art mAbs purification, focusing on multimodal chromatography as one viable options upgrade established purification train.